Avita Medical Inc.
ASX: AVH
AVH delivers major revenue surge.
(Source: TradingView) 3-Month Performance Profile of AVH compared to the S&P/ASX 200 (XJO).
The company delivered robust Q1 FY25 results, with revenue surging 75% YoY to $29.5 million. The launch of RECELL GO in May 2024 and RECELL GO mini in December 2024 supported wider clinical adoption, especially across U.S. centers, which con
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
